

Special Issue

Updates in Novel Markers on Tumors of the Urological Tract: From Diagnosis and Prognosis to Therapy and Clinical Efficacy

Message from the Guest Editors

Urothelial carcinoma (UC) represents a frequent genitourinary malignancy found predominately in the bladder. Despite recent efforts and developments, patients with UC experience poor prognoses and disease recurrences. Biomarkers to predict prognosis and treatment response have been largely investigated. Although promising, a standardized approach and a consensus are still lacking. The recent development of new therapeutic strategies, such as antibody-drug conjugates, monoclonal antibodies targeting a specific cell surface antigen, has stimulated additional investigation of molecular targets. In this setting, further research is needed to better stratify patient risk, predict treatment efficacy, and assess targeted therapeutic approaches. This Special Issue aims to collect the most recent developments in tumor biomarkers with prognostic and predictive value among NMI and MI or metastatic UC. This Issue will also collect recent advances in promising or novel therapeutic targets for local treatment or systemic therapy in the entire spectrum of tumors of the urological tract, including retrospective and prospective results from clinical trials or small mono-institutional series.

Guest Editors

Dr. Piergiuseppe Colombo

Dr. Paolo Andrea Zucali

Dr. Marina Valeri

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/134990

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)